Search

Your search keyword '"Vergne, Laurence"' showing total 2 results
Start Over Author "Vergne, Laurence" Region burkina faso
2 results on '"Vergne, Laurence"'

1. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.

Author

Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-Huong N, Diop H, Kane CT, Valéa D, Rouet F, Joulia-Ekaza D, Toni TD, Nerrienet E, Ngole EM, Delaporte E, Costagliola D, Peeters M, and Chaix ML

Subjects
Adult, Burkina Faso epidemiology, Cote d'Ivoire epidemiology, Female, Genotype, HIV Protease genetics, HIV Reverse Transcriptase genetics, HIV-1 genetics, Humans, Molecular Sequence Data, Phylogeny, Pregnancy, Prevalence, Senegal epidemiology, Sequence Analysis, DNA, Thailand epidemiology, Vietnam epidemiology, Young Adult, Anti-HIV Agents therapeutic use, Drug Resistance, Viral genetics, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections virology, HIV-1 drug effects, Mutation, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious virology
Abstract

The frequency of transmitted HIV drug resistance (HIVDR) was evaluated in the context of rapid scale-up of antiretroviral treatment in Thailand, Vietnam, Burkina Faso, Côte d'Ivoire, and Senegal by using an adaptation of the WHO generic protocol of the HIV Drug Resistance Threshold Survey (HIVDR-TS) for sample collection and classification. Resistance-associated mutations were interpreted using the 2009 WHO list for epidemiological surveys. We included 266 subjects from the five study sites. Of the 266 RT and PR sequences analyzed, two from Vietnam harbored virus with major drug resistance mutations (G190A in RT for one individual and M46I in PR for the second individual). Phylogenetic analysis revealed that CRF01&#95;AE predominates (>90%) in Thailand and Vietnam. CRF02 (>65%) cocirculates with other HIV-1 variants in Senegal and Côte d'Ivoire. The prevalence of HIVDRM is scored as low (< or = 5%) in all the five sites for the three drug classes analyzed. A continuous population survey for HIVDRM will provide a rational basis for maintaining or changing the current first line regimen in these countries.

Published
2009
Full Text
View/download PDF

2. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.

Author

Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, Noumssi N, Tardy M, Sawadogo A, Drabo J, Hien H, Zekeng L, Delaporte E, and Peeters M

Subjects
Adult, Antiretroviral Therapy, Highly Active, Burkina Faso, Cameroon, Female, HIV Infections diagnosis, HIV Infections drug therapy, HIV Protease genetics, Humans, Male, Middle Aged, Mutation, National Health Programs, Population Surveillance, RNA-Directed DNA Polymerase genetics, Drug Resistance, Multiple, Viral genetics, HIV Infections genetics, HIV Protease Inhibitors therapeutic use, HIV-1 genetics, Reverse Transcriptase Inhibitors therapeutic use
Abstract

We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n = 1], M41L+T69S [n = 1]), four to non-NRTIs (NNRTIs; V106A/V [n = 1] and V1081 [n = 3]) and two to protease inhibitors (PIs; L33F [n = 2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results